IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Capital Investment Services of America Inc.

Capital Investment Services of America Inc. raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.9% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 39,534 shares of the company’s stock after acquiring an additional 739 shares during the quarter. IDEXX Laboratories makes up about 1.7% of Capital Investment Services of America Inc.’s holdings, making the stock its 28th largest holding. Capital Investment Services of America Inc.’s holdings in IDEXX Laboratories were worth $16,602,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Blue Zone Wealth Advisors LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth $3,958,000. Villere ST Denis J & Co. LLC grew its stake in IDEXX Laboratories by 2.6% in the 4th quarter. Villere ST Denis J & Co. LLC now owns 62,442 shares of the company’s stock valued at $25,816,000 after acquiring an additional 1,556 shares during the last quarter. Alberta Investment Management Corp grew its stake in IDEXX Laboratories by 25.3% in the 4th quarter. Alberta Investment Management Corp now owns 10,900 shares of the company’s stock valued at $4,506,000 after acquiring an additional 2,200 shares during the last quarter. Banque Transatlantique SA acquired a new stake in IDEXX Laboratories in the 4th quarter valued at about $2,681,000. Finally, Waycross Partners LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at about $13,411,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director now directly owns 1,801 shares in the company, valued at $922,724.34. This represents a 41.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Down 0.8%

Shares of IDXX stock opened at $522.70 on Friday. The firm has a market cap of $42.04 billion, a P/E ratio of 48.99, a PEG ratio of 3.41 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $530.73. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm’s 50-day simple moving average is $473.11 and its 200-day simple moving average is $444.30.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company’s revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.71 EPS. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Stifel Nicolaus increased their price objective on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a “hold” rating in a research note on Monday, May 19th. Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a research note on Monday, May 5th. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, May 30th. Finally, Leerink Partners upped their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $546.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.